Company
e-Therapeutics PLC
LON:ETX
e-Therapeutics PLC is integrating computational power and biology to accelerate the discovery of life-transforming RNAi medicines. The company has developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology to fully capture and interrogate human disease complexity. e-Therapeutics' multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support.
153 stories · page 1 of 8
e-therapeutics raises £13.5mln via a direct subscription by funds run by M&G
The cash influx will be used to supercharge the development of its gene silencing technology
e-Therapeutics files eight more patents for its gene silencing technology
The patent applications relate to innovation coming from the company’s work on its pre-clinical siRNA candidates
e-Therapeutics hails 'significantly strengthened' cash position as it looks to kick on after a successful year
The company is a specialist in computational drug discovery and gene silencing
e-therapeutics achieves milestone in Galapagos collaboration
“In keeping with previous e-therapeutics projects, the hit rate in the identification of active compounds was several orders of magnitude higher than the industry standard, further validating e-therapeutics' robust computational biology met
Archive
Small Cap Wrap - E-Therapeutics, Faron Pharma, Ondine Biomedical, and more...
5th April 2022*A corporate client of Hybridan LLPDish of the dayJoiners:LSE:ADVT has been readmitted to the Main Market following the reverse takeover of M&C Saatchi.Leavers:Simigon and Clinigen have left AIM.What’s cooking in the IPO kitch
e-therapeutics teams up with US group iTeos Therapeutics to discover potential new cancer treatments
The Oxford-based group will receive undisclosed but material upfront and near-term cash payments as a result of the tie-up
Proactive news headlines: e-Therapeutics, Franchise Brands, MGC Pharmaceuticals...
A round-up of some of the day's highlights from the Proactive Investors newswire
e-Therapeutics eyes industry partnerships following the successful testing of its technology
A separate results statement revealed the company was in a financially strong position to build on this progress
e-Therapeutics unveils new patent filings
The patents are related to the firm's RNAi platform technology for liver gene silencing
e-therapeutics to make US debut on OTCQX Best Market today
Chief executive Ali Mortazavi said: “US institutional and retail investors will now be able to buy and sell our shares via online trading platforms and mobile apps"